Given the differential expression of AKT isoforms 1 and 2 and the low levels of expression of AKT3, the development of AKT 1/2 isoform selective inhibitors may be advantageous in cancer settings where the relative abundance of each isoform is specific to each cancer type. This evidence concerns the gene AKT3 and cancer.